Diphenhydramine hydrochloride in the injectable form is effective in adults and pediatric patients, other than premature infants and neonates, for the following conditions when diphenhydramine hydrochloride in the oral form is impractical. For amelioration of allergic reactions to blood or plasma, in anaphylaxis as an adjunct to epinephrine and other standard measures after the acute symptoms have been controlled,...
THIS PRODUCT IS FOR INTRAVENOUS OR INTRAMUSCULAR ADMINISTRATION ONLY. Diphenhydramine hydrochloride in the injectable form is indicated when the oral form is impractical. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. DOSAGE SHOULD BE INDIVIDUALIZED ACCORDING TO THE NEEDS AND THE RESPONSE OF THE PATIENT...
Rx only
Diphenhydramine hydrochloride is an antihistamine drug having the chemical name 2-(Diphenylmethoxy)-N,N-dimethylethylamine hydrochloride. It occurs as a white, crystalline powder, is freely soluble in water and alcohol and has a molecular weight of 291.82. The molecular formula is C17H21NO • HCl and the structural formula is as follows:
Diphenhydramine hydrochloride in the parenteral form is a sterile, pyrogen-free solution available in a concentration of 50 mg of diphenhydramine hydrochloride per mL for intramuscular or intravenous use. The solution for parenteral use has been adjusted to a pH between 4 and 6.5 with either sodium hydroxide or hydrochloric acid.
Diphenhydramine hydrochloride is an antihistamine with anticholinergic (drying) and sedative side effects. Antihistamines appear to compete with histamine for cell receptor sites on effector cells.
Diphenhydramine hydrochloride in the injectable form has a rapid onset of action. Diphenhydramine hydrochloride is widely distributed throughout the body, including the CNS. A portion of the drug is excreted unchanged in the urine, while the rest is metabolized via the liver. Detailed information on the pharmacokinetics of Diphenhydramine Hydrochloride Injection is not available.
Diphenhydramine hydrochloride in the injectable form is effective in adults and pediatric patients, other than premature infants and neonates, for the following conditions when diphenhydramine hydrochloride in the oral form is impractical.
For amelioration of allergic reactions to blood or plasma, in anaphylaxis as an adjunct to epinephrine and other standard measures after the acute symptoms have been controlled, and for other uncomplicated allergic conditions of the immediate type when oral therapy is impossible or contraindicated.
For active treatment of motion sickness.
For use in parkinsonism, when oral therapy is impossible or contraindicated, as follows: parkinsonism in the elderly who are unable to tolerate more potent agents; mild cases of parkinsonism in other age groups, and in other cases of parkinsonism in combination with centrally acting anticholinergic agents.
This drug should not be used in neonates or premature infants.
Because of the higher risk of antihistamines for infants generally, and for neonates and prematures in particular, antihistamine therapy is contraindicated in nursing mothers.
Because of the risk of local necrosis, this drug should not be used as a local anesthetic.
Hypersensitivity to diphenhydramine hydrochloride and other antihistamines of similar chemical structure.
Antihistamines should be used with considerable caution in patients with narrow-angle glaucoma, stenosing peptic ulcer, pyloroduodenal obstruction, symptomatic prostatic hypertrophy, or bladder-neck obstruction.
Local necrosis has been associated with the use of subcutaneous or intradermal use of intravenous diphenhydramine.
In pediatric patients, especially, antihistamines in overdosage may cause hallucinations, convulsions, or death.
As in adults, antihistamines may diminish mental alertness in pediatric patients. In the young pediatric patient, particularly, they may produce excitation.
Antihistamines are more likely to cause dizziness, sedation, and hypotension in elderly patients.
Diphenhydramine hydrochloride has an atropine-like action and, therefore, should be used with caution in patients with a history of bronchial asthma, increased intraocular pressure, hyperthyroidism, cardiovascular disease or hypertension. Use with caution in patients with lower respiratory disease including asthma.
Patients taking diphenhydramine hydrochloride should be advised that this drug may cause drowsiness and has an additive effect with alcohol.
Patients should be warned about engaging in activities requiring mental alertness such as driving a car or operating appliances, machinery, etc.
Diphenhydramine hydrochloride has additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, etc).
MAO inhibitors prolong and intensify the anticholinergic (drying) effects of antihistamines.
Long-term studies in animals to determine mutagenic and carcinogenic potential have not been performed.
Reproduction studies have been performed in rats and rabbits at doses up to 5 times the human dose and have revealed no evidence of impaired fertility or harm to the fetus due to diphenhydramine hydrochloride. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.
Diphenhydramine should not be used in neonates and premature infants (see CONTRAINDICATIONS).
Diphenhydramine may diminish mental alertness, or in the young pediatric patient, cause excitation. Overdosage may cause hallucinations, convulsions, or death (see WARNINGS and OVERDOSAGE).
See also DOSAGE AND ADMINISTRATION section.
The most frequent adverse reactions are italicized:
General
Urticaria; drug rash; anaphylactic shock; photosensitivity; excessive perspiration; chills; dryness of mouth, nose, and throat.
Cardiovascular System
Hypotension, headache, palpitations, tachycardia, extrasystoles.
Hematologic System
Hemolytic anemia, thrombocytopenia, agranulocytosis.
Nervous System
Sedation, sleepiness, dizziness, disturbed coordination, fatigue, confusion, restlessness, excitation, nervousness, tremor, irritability, insomnia, euphoria, paresthesia, blurred vision, diplopia, vertigo, tinnitus, acute labyrinthitis, neuritis, convulsions.
Gastrointestinal System
Epigastric distress, anorexia, nausea, vomiting, diarrhea, constipation.
Genitourinary System
Urinary frequency, difficult urination, urinary retention, early menses.
Respiratory System
Thickening of bronchial secretions, tightness of chest or throat and wheezing, nasal stuffiness.
Antihistamine overdosage reactions may vary from central nervous system depression to stimulation. Stimulation is particularly likely in pediatric patients. Atropine-like signs and symptoms; dry mouth; fixed, dilated pupils; flushing; and gastrointestinal symptoms may also occur.
Stimulants should not be used.
Vasopressors may be used to treat hypotension.
THIS PRODUCT IS FOR INTRAVENOUS OR INTRAMUSCULAR ADMINISTRATION ONLY.
Diphenhydramine hydrochloride in the injectable form is indicated when the oral form is impractical.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
DOSAGE SHOULD BE INDIVIDUALIZED ACCORDING TO THE NEEDS AND THE RESPONSE OF THE PATIENT.
5 mg/kg/24 hours or 150 mg/m2/24 hours. Maximum daily dosage is 300 mg. Divide into four doses, administered intravenously at a rate generally not exceeding 25 mg/min, or deep intramuscularly.
10 mg to 50 mg intravenously at a rate generally not exceeding 25 mg/min, or deep intramuscularly; 100 mg if required; maximum daily dosage is 400 mg.
Diphenhydramine Hydrochloride Injection, USP is available as:
| Unit of Sale | Concentration |
|---|---|
| NDC 0409-2290-31 Carton of 10 1 mL fill in 2 mL Carpuject™ Single-dose cartridge with Luer Lock for the Carpuject™ Syringe System | 50 mg/mL |
Carpuject™ Single-dose cartridges with Luer Lock are packaged in a Slim-Pak™ tamper detection package. Note that a needle is not included.
Instructions for Use of the Syringe Systems
Instructions for using the Carpuject™ Syringe are available with the reusable Carpuject™ Holder, List 2049-02.
Carpuject™ Single-dose cartridges are to be used ONLY with Carpuject™ Holders, List 2049-02.
Store at 20 to 25°C (68 to 77°F). [See USP Controlled Room Temperature.]
Protect from freezing and light. Retain in carton until time of use.
Distributed by Hospira, Inc., Lake Forest, IL 60045 USA 
LAB-1300-3.0
Revised 05/2019
1 mL Single-use Carpuject™
Sterile Cartridge Unit with Luer Lock
DiphenhydrAMINE
HCl Injection, USP
50 mg/mL
For Intravenous or Intramuscular Use
Rx only
HIGH POTENCY
PROTECT FROM LIGHT
Hospira
NDC 0409-2290-03
RL–5589
1 mL
Single-use
NDC 0409-2290-31
Rx only
10 Carpuject™
Sterile Cartridge Units
with Luer Lock
Needle not included
SLIM-PAK™
Tamper Detection Package
DiphenhydrAMINE
HCl Injection, USP
50 mg/mL
HIGH POTENCY
For Intravenous or
Intramuscular Use
Carpuject Cartridges are to be used
ONLY with Carpuject Holders.
Hospira
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 0409-2290-03 | ML - Milliliter | 0409-2290 | 7883c166-5f53-4d39-a53e-73a05cfd727d | 1 | 2017-09-11 |
| 0409-2290-11 | ML - Milliliter | 0409-2290 | 812fa907-7024-4aa4-83aa-91a07608d99d | 1 | 2022-06-06 |
| 0409-2290-31 | ML - Milliliter | 0409-2290 | e798365d-9ce4-48d3-9c12-c31706accf6d | 1 | 2012-07-24 |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| DIPHENHYDRAMINE HYDROCHLORIDE | ACTIVE INGREDIENT | TC2D6JAD40 | 14 | |
| DIPHENHYDRAMINE | ACTIVE MOIETY | 8GTS82S83M | 14 | |
| HYDROCHLORIC ACID | INACTIVE INGREDIENT | QTT17582CB | 14 | |
| SODIUM HYDROXIDE | INACTIVE INGREDIENT | 55X04QC32I | 14 | |
| WATER | INACTIVE INGREDIENT | 059QF0KO0R | 14 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 0409-2290 | 0409-2290-03, 0409-2290-31 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| DIPHENHYDRAMINE HYDROCHLORIDE | TC2D6JAD40 | ACTIB |
| SODIUM HYDROXIDE | 55X04QC32I | IACT |
| HYDROCHLORIC ACID | QTT17582CB | IACT |
| WATER | 059QF0KO0R | IACT |
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| HYDROCHLORIC ACID | HYDROCHLORIC ACID | QTT17582CB | SUSPENSION, EXTENDED RELEASE / ORAL | ADJ PH | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | SOLUTION / IRRIGATION | ADJ PH | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRATHECAL | ADJ PH | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | INJECTION / INTRAPLEURAL | ADJ PH | ||
| HYDROCHLORIC ACID | HYDROCHLORIC ACID | QTT17582CB | INJECTION / INTRASPINAL | ADJ PH | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | SOLUTION / EPIDURAL | ADJ PH | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | GEL / VAGINAL | 20 mg | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | INJECTION / INTRADERMAL | ADJ PH | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | LIQUID / TOPICAL | ADJ PH | ||
| HYDROCHLORIC ACID | HYDROCHLORIC ACID | QTT17582CB | INJECTION / INTRAVITREAL | ADJ PH | ||
| HYDROCHLORIC ACID | HYDROCHLORIC ACID | QTT17582CB | GEL / OPHTHALMIC | ADJ PH | ||
| HYDROCHLORIC ACID | HYDROCHLORIC ACID | QTT17582CB | CAPSULE / ORAL | 7 mg | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAMUSCULAR | 0.35 %w/v | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / PARENTERAL | ADJ PH | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | INJECTION / INTRALESIONAL | ADJ PH | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | CAPSULE, COATED PELLETS / ORAL | 0.01 mg | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | GRANULE, FOR SUSPENSION / ORAL | ADJ PH | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | INJECTION / INTRA-AMNIOTIC | ADJ PH | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | INJECTION / ENDOTRACHEAL | ADJ PH | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | INJECTION / INTRASPINAL | ADJ PH | ||
| HYDROCHLORIC ACID | HYDROCHLORIC ACID | QTT17582CB | INJECTION / PARENTERAL | ADJ PH | ||
| HYDROCHLORIC ACID | HYDROCHLORIC ACID | QTT17582CB | INJECTION, SOLUTION / EPIDURAL | ADJ PH | ||
| HYDROCHLORIC ACID | HYDROCHLORIC ACID | QTT17582CB | CREAM / TOPICAL | 38 mg | ||
| HYDROCHLORIC ACID | HYDROCHLORIC ACID | QTT17582CB | SOLUTION/ DROPS / TOPICAL | ADJ PH | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | INJECTION, POWDER, FOR SOLUTION / INTRADERMAL | ADJ PH | ||
| HYDROCHLORIC ACID | HYDROCHLORIC ACID | QTT17582CB | SHAMPOO / TOPICAL | 104 mg | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | INJECTION, SOLUTION / INTRAVASCULAR | ADJ PH | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | SOLUTION / INTRA-ARTERIAL | ADJ PH | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | GEL / TOPICAL | 70 mg | ||
| HYDROCHLORIC ACID | HYDROCHLORIC ACID | QTT17582CB | SOLUTION/ DROPS / AURICULAR (OTIC) | ADJ PH | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | CAPSULE, DELAYED RELEASE / ORAL | 0.25 mg | ||
| HYDROCHLORIC ACID | HYDROCHLORIC ACID | QTT17582CB | INJECTION / SUBMUCOSAL | ADJ PH | ||
| HYDROCHLORIC ACID | HYDROCHLORIC ACID | QTT17582CB | INJECTION, POWDER, FOR SOLUTION / INTRATHECAL | ADJ PH | ||
| HYDROCHLORIC ACID | HYDROCHLORIC ACID | QTT17582CB | SOLUTION / AURICULAR (OTIC) | 0.37 %w/v | ||
| HYDROCHLORIC ACID | HYDROCHLORIC ACID | QTT17582CB | INJECTION, SOLUTION / INFILTRATION | ADJ PH | ||
| HYDROCHLORIC ACID | HYDROCHLORIC ACID | QTT17582CB | SUSPENSION/ DROPS / TOPICAL | ADJ PH | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | INJECTABLE, LIPOSOMAL / INTRAVENOUS | ADJ PH | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | INJECTION, SUSPENSION / INTRAMUSCULAR | ADJ PH | ||
| HYDROCHLORIC ACID | HYDROCHLORIC ACID | QTT17582CB | AEROSOL, METERED / RESPIRATORY (INHALATION) | 0.7 %w/w | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | SOLUTION / INTRAVENOUS | 2.78 %w/v | ||
| HYDROCHLORIC ACID | HYDROCHLORIC ACID | QTT17582CB | INJECTION, POWDER, FOR SOLUTION / PARENTERAL | ADJ PH | ||
| HYDROCHLORIC ACID | HYDROCHLORIC ACID | QTT17582CB | SUSPENSION / ORAL | 100 mg | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | POWDER / RESPIRATORY (INHALATION) | ADJ PH | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | INJECTION, SOLUTION / INTRA-ARTERIAL | ADJ PH | ||
| HYDROCHLORIC ACID | HYDROCHLORIC ACID | QTT17582CB | INJECTION, SUSPENSION / INTRAVITREAL | ADJ PH | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | ELIXIR / ORAL | ADJ PH | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | TABLET, DELAYED RELEASE / ORAL | 4 mg | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | INJECTION, SUSPENSION, LIPOSOMAL / INTRAVENOUS | ADJ PH | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | INJECTION, POWDER, FOR SOLUTION / INTRATHECAL | ADJ PH | ||
| HYDROCHLORIC ACID | HYDROCHLORIC ACID | QTT17582CB | INJECTION, SOLUTION / INTRAVENOUS | 1037 mg | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | CAPSULE, COATED / ORAL | 0.08 mg | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | LIQUID / ORAL | 2 mg/5ml | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | INJECTION / RETROBULBAR | ADJ PH | ||
| HYDROCHLORIC ACID | HYDROCHLORIC ACID | QTT17582CB | SUSPENSION/ DROPS / OPHTHALMIC | ADJ PH | ||
| HYDROCHLORIC ACID | HYDROCHLORIC ACID | QTT17582CB | INJECTION / INTRACARDIAC | ADJ PH | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | TABLET, ORALLY DISINTEGRATING / ORAL | 1 mg | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | SOLUTION / TOPICAL | 39 mg | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | DISC / TOPICAL | ADJ PH | ||
| HYDROCHLORIC ACID | HYDROCHLORIC ACID | QTT17582CB | GEL / TOPICAL | 10 mg | ||
| HYDROCHLORIC ACID | HYDROCHLORIC ACID | QTT17582CB | INJECTION, POWDER, FOR SUSPENSION / INTRAVENOUS | 4.17 mg |
All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| A040140-001 | DIPHENHYDRAMINE HYDROCHLORIDE | DIPHENHYDRAMINE HYDROCHLORIDE | 50MG/ML | INJECTABLE / INJECTION | 1998-11-20 |
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-09-14 22:38:34 | 2026-08 | A040140-001 | DIPHENHYDRAMINE HYDROCHLORIDE | 50MG/ML | INJECTABLE / INJECTION | 1998-11-20 | 84e616aacf4f… | ||
| 2026-08-18 06:07:40 | 2026-07 | A040140-001 | DIPHENHYDRAMINE HYDROCHLORIDE | 50MG/ML | INJECTABLE / INJECTION | 1998-11-20 | caaa826d4ba7… | ||
| 2026-02-19 14:30 UTC | 2026-02 | A040140-001 | DIPHENHYDRAMINE HYDROCHLORIDE | 50MG/ML | INJECTABLE / INJECTION | 1998-11-20 | 011fe1cb6892… | ||
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A040140-001 | DIPHENHYDRAMINE HYDROCHLORIDE | 50MG/ML | INJECTABLE / INJECTION | 1998-11-20 | 31067a03dcf5… | ||
| 2025-08-23 18:47 UTC | 2025-08 | A040140-001 | DIPHENHYDRAMINE HYDROCHLORIDE | 50MG/ML | INJECTABLE / INJECTION | 1998-11-20 | 6a471c1ec25d… | ||
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A040140-001 | DIPHENHYDRAMINE HYDROCHLORIDE | 50MG/ML | INJECTABLE / INJECTION | 1998-11-20 | fd3edfee7708… | ||
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A040140-001 | DIPHENHYDRAMINE HYDROCHLORIDE | 50MG/ML | INJECTABLE / INJECTION | 1998-11-20 | b8a1b40f171c… | ||
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | A040140-001 | DIPHENHYDRAMINE HYDROCHLORIDE | 50MG/ML | INJECTABLE / INJECTION | 1998-11-20 | 03ed91905a0d… | ||
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | A040140-001 | DIPHENHYDRAMINE HYDROCHLORIDE | 50MG/ML | INJECTABLE / INJECTION | 1998-11-20 | 2680178bc6a6… | ||
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | A040140-001 | DIPHENHYDRAMINE HYDROCHLORIDE | 50MG/ML | INJECTABLE / INJECTION | 1998-11-20 | 5bbf6a4d5a75… | ||
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | A040140-001 | DIPHENHYDRAMINE HYDROCHLORIDE | 50MG/ML | INJECTABLE / INJECTION | 1998-11-20 | d8e5a09893c0… | ||
| 2024-10-29 15:01 UTC | 2024-10 | A040140-001 | DIPHENHYDRAMINE HYDROCHLORIDE | 50MG/ML | INJECTABLE / INJECTION | 1998-11-20 | d06236e962d9… | ||
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | A040140-001 | DIPHENHYDRAMINE HYDROCHLORIDE | 50MG/ML | INJECTABLE / INJECTION | 1998-11-20 | 79d66fd596c7… | ||
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | A040140-001 | DIPHENHYDRAMINE HYDROCHLORIDE | 50MG/ML | INJECTABLE / INJECTION | 1998-11-20 | 301d65b070ca… | ||
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | A040140-001 | DIPHENHYDRAMINE HYDROCHLORIDE | 50MG/ML | INJECTABLE / INJECTION | 1998-11-20 | 1e350fbaab3a… | ||
| 2024-05-31 18:47 UTC | 2024-05 | A040140-001 | DIPHENHYDRAMINE HYDROCHLORIDE | 50MG/ML | INJECTABLE / INJECTION | 1998-11-20 | 8072bd15b7f6… | ||
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | A040140-001 | DIPHENHYDRAMINE HYDROCHLORIDE | 50MG/ML | INJECTABLE / INJECTION | 1998-11-20 | 5c6f7cd8ea54… | ||
| 2022-04-08 23:34 UTC | 2022-04 | A040140-001 | DIPHENHYDRAMINE HYDROCHLORIDE | 50MG/ML | INJECTABLE / INJECTION | 1998-11-20 | 5d02ea3f76ae… | ||
| 2022-04-04 05:41 UTC | 2022-04 | A040140-001 | DIPHENHYDRAMINE HYDROCHLORIDE | 50MG/ML | INJECTABLE / INJECTION | AP | 1998-11-20 | 4b0b4de00fa7… | |
| 2019-12-13 00:20 UTC | 2019-12 | A040140-001 | DIPHENHYDRAMINE HYDROCHLORIDE | 50MG/ML | INJECTABLE / INJECTION | AP | 1998-11-20 | 74a2ff9319b5… | |
| 2022-03-09 01:35 UTC | 2022-03 | A040140-001 | DIPHENHYDRAMINE HYDROCHLORIDE | 50MG/ML | INJECTABLE / INJECTION | AP | 1998-11-20 | bb7c543d1eb4… | |
| 2021-12-28 21:50 UTC | 2021-12 | A040140-001 | DIPHENHYDRAMINE HYDROCHLORIDE | 50MG/ML | INJECTABLE / INJECTION | AP | 1998-11-20 | 782e0a99824c… | |
| 2021-05-05 16:15 UTC · 3 captures of this ZIP | 2021-05 | A040140-001 | DIPHENHYDRAMINE HYDROCHLORIDE | 50MG/ML | INJECTABLE / INJECTION | AP | 1998-11-20 | 87673890dc5c… | |
| 2021-03-12 10:30 UTC | 2021-03 | A040140-001 | DIPHENHYDRAMINE HYDROCHLORIDE | 50MG/ML | INJECTABLE / INJECTION | AP | 1998-11-20 | 5aa47cf7b7d7… | |
| 2020-12-22 03:56 UTC | 2020-12 | A040140-001 | DIPHENHYDRAMINE HYDROCHLORIDE | 50MG/ML | INJECTABLE / INJECTION | AP | 1998-11-20 | 8869cabd3fbd… | |
| 2020-11-12 02:37 UTC | 2020-11 | A040140-001 | DIPHENHYDRAMINE HYDROCHLORIDE | 50MG/ML | INJECTABLE / INJECTION | 1998-11-20 | c0c555d07b60… | ||
| 2019-12-14 00:12 UTC | 2019-12 | A040140-001 | DIPHENHYDRAMINE HYDROCHLORIDE | 50MG/ML | INJECTABLE / INJECTION | AP | 1998-11-20 | 3f01610625f2… | |
| 2019-09-15 20:21 UTC | 2019-09 | A040140-001 | DIPHENHYDRAMINE HYDROCHLORIDE | 50MG/ML | INJECTABLE / INJECTION | AP | 1998-11-20 | b00525d2431f… | |
| 2019-07-19 19:46 UTC | 2019-07 | A040140-001 | DIPHENHYDRAMINE HYDROCHLORIDE | 50MG/ML | INJECTABLE / INJECTION | AP | 1998-11-20 | ea99ee380514… | |
| 2024-03-16 18:09 UTC · 4 captures of this ZIP | 2024-03 | A040140-001 | DIPHENHYDRAMINE HYDROCHLORIDE | 50MG/ML | INJECTABLE / INJECTION | 1998-11-20 | 6a51e52b5d6a… | ||
| 2024-02-18 07:12 UTC | 2024-02 | A040140-001 | DIPHENHYDRAMINE HYDROCHLORIDE | 50MG/ML | INJECTABLE / INJECTION | 1998-11-20 | 1c564ffb4f44… | ||
| 2023-12-20 04:57 UTC | 2023-12 | A040140-001 | DIPHENHYDRAMINE HYDROCHLORIDE | 50MG/ML | INJECTABLE / INJECTION | 1998-11-20 | ea1830bbd6c7… | ||
| 2023-11-28 05:40 UTC · 2 captures of this ZIP | 2023-11 | A040140-001 | DIPHENHYDRAMINE HYDROCHLORIDE | 50MG/ML | INJECTABLE / INJECTION | 1998-11-20 | a72a2bbeb626… | ||
| 2023-10-25 00:34 UTC · 2 captures of this ZIP | 2023-10 | A040140-001 | DIPHENHYDRAMINE HYDROCHLORIDE | 50MG/ML | INJECTABLE / INJECTION | 1998-11-20 | 9b2671bbb829… | ||
| 2023-07-15 15:27 UTC · 2 captures of this ZIP | 2023-07 | A040140-001 | DIPHENHYDRAMINE HYDROCHLORIDE | 50MG/ML | INJECTABLE / INJECTION | 1998-11-20 | a67488948f0b… | ||
| 2023-06-13 01:57 UTC · 3 captures of this ZIP | 2023-06 | A040140-001 | DIPHENHYDRAMINE HYDROCHLORIDE | 50MG/ML | INJECTABLE / INJECTION | 1998-11-20 | 3f0d92c62455… | ||
| 2023-05-13 08:27 UTC | 2023-05 | A040140-001 | DIPHENHYDRAMINE HYDROCHLORIDE | 50MG/ML | INJECTABLE / INJECTION | 1998-11-20 | 053a50430f4f… | ||
| 2023-01-26 05:58 UTC | 2023-01 | A040140-001 | DIPHENHYDRAMINE HYDROCHLORIDE | 50MG/ML | INJECTABLE / INJECTION | 1998-11-20 | 3bdfa0b2c4d7… | ||
| 2022-11-12 20:34 UTC · 5 captures of this ZIP | 2022-11 | A040140-001 | DIPHENHYDRAMINE HYDROCHLORIDE | 50MG/ML | INJECTABLE / INJECTION | 1998-11-20 | 3a93d1ddd44b… | ||
| 2022-10-28 04:53 UTC | 2022-10 | A040140-001 | DIPHENHYDRAMINE HYDROCHLORIDE | 50MG/ML | INJECTABLE / INJECTION | 1998-11-20 | f41ea6bd6efb… |
| Captured | Edition | Application-product | TE code | Order | Source SHA-256 |
|---|---|---|---|---|---|
| 2022-04-04 05:41 UTC | 2022-04 | A040140-001 | AP | 1 | 4b0b4de00fa7… |
| 2019-12-13 00:20 UTC | 2019-12 | A040140-001 | AP | 1 | 74a2ff9319b5… |
| 2022-03-09 01:35 UTC | 2022-03 | A040140-001 | AP | 1 | bb7c543d1eb4… |
| 2021-12-28 21:50 UTC | 2021-12 | A040140-001 | AP | 1 | 782e0a99824c… |
| 2021-05-05 16:15 UTC · 3 captures of this ZIP | 2021-05 | A040140-001 | AP | 1 | 87673890dc5c… |
| 2021-03-12 10:30 UTC | 2021-03 | A040140-001 | AP | 1 | 5aa47cf7b7d7… |
| 2020-12-22 03:56 UTC | 2020-12 | A040140-001 | AP | 1 | 8869cabd3fbd… |
| 2019-12-14 00:12 UTC | 2019-12 | A040140-001 | AP | 1 | 3f01610625f2… |
| 2019-09-15 20:21 UTC | 2019-09 | A040140-001 | AP | 1 | b00525d2431f… |
| 2019-07-19 19:46 UTC | 2019-07 | A040140-001 | AP | 1 | ea99ee380514… |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| 92df626a-3da2-47ed-8ea1-f69f07b66257 | 3cfa4719-e616-4aa7-d8a0-98df76177136 | 2020-11-17 | Warnings, Adverse reactions | 3cfa4719-e616-4aa7-d8a0-98df76177136 |
Adverse event summaries are temporarily unavailable. Other product information remains available.